当前位置: 首页 >> 检索结果
101. Novel Contrast-Derived Indices of Coronary Microvascular Function: Potential Clinical and Cost Benefits.
作者: Daniel T Y Ang.;Damien G Collison.;Ross J McGeoch.;David Carrick.;Robert A Sykes.;Conor Bradley.;Anna L Kamdar.;Andy Jong.;Richard A Brogan.;David A MacDougall.;Peter J McCartney.;J Paul Rocchiccioli.;Andrew P Apps.;C Aengus Murphy.;Keith E Robertson.;Aadil Shaukat.;Angie Ghattas.;Francis R Joshi.;Arvind Sood.;Richard I S Good.;Brian O'Rourke.;Hany Eteiba.;M Mitchell Lindsay.;Alex McConnachie.;Colin Berry.
来源: Circ Cardiovasc Interv. 2025年18卷6期e015058页
Intravenous adenosine induces stable myocardial hyperemia for coronary microvascular function testing. Iodinated radiographic contrast media induce transient, submaximal hyperemia. We assessed the feasibility, diagnostic value, and potential cost-effectiveness of contrast-derived indices of microvascular function.
102. COOPERATIVE-PFA: A Three-Arm Randomized Controlled Trial.
作者: Veronika Sochorová.;Veronika Kunštátová.;Pavel Osmančík.;František Duška.;Dalibor Heřman.;Petr Waldauf.;Lukáš Povišer.;Jakub Karch.;Lucie Znojilová.;Věra Filipcová.;Jana Hozmanová.;Jana Veselá.;Marek Hozman.
来源: Circulation. 2025年152卷3期150-159页
Deep analgosedation (DAS) or general anesthesia is mandatory for pulsed-field ablation of atrial fibrillation. In contrast to DAS, general anesthesia (conventional or total intravenous anesthesia [TIVA]) requires airway management. To find the optimal sedation regimen, this study compared ketamine-remimazolam DAS and propofol-opioid TIVA with propofol-opioid DAS, focusing on sedation-related adverse events.
103. Device-Related Complications in Transvenous Versus Subcutaneous Defibrillator Therapy During Long-Term Follow-Up: The PRAETORIAN-XL Trial.
作者: Louise R A Olde Nordkamp.;Jolien A de Veld.;Abdul Ghani.;Jürgen Kuschyk.;Hendrik Bonnemeier.;Kerstin Bode.;Lucas V A Boersma.;Anouk de Weger.;Jonas S S G de Jong.;Ward P J Jansen.;Marco Alings.;Nick Bijsterveld.;Mikhael F El-Chami.;Rypko J Beukema.;Kevin Vernooy.;Berit T Philbert.;Petr Neuzil.;Peter Nordbeck.;Jurren M van Opstal.;Cornelis P Allaart.;David J Wright.;Michael Knaut.;Timothy R Betts.;Zachary I Whinnett.;Pier D Lambiase.;Joris R de Groot.;Alexandru B Chicos.;Dimitry Nemirovksy.;Stefan Kääb.;Suneet Mittal.;Alida E Borger van der Burg.;Leonard A Dijkshoorn.;Shari Pepplinkhuizen.;Willeke van der Stuijt.;Jose M Dizon.;Marc A Miller.;Elijah R Behr.;Martin C Burke.;Kirsten M Kooiman.;Anne-Floor B E Quast.;Tom F Brouwer.;Arthur A M Wilde.;Lonneke Smeding.;Reinoud E Knops.; .
来源: Circulation. 2025年152卷3期172-182页
The PRAETORIAN trial (A Prospective, Randomized Comparison of Subcutaneous and Transvenous Implantable Cardioverter Defibrillator Therapy) investigated the efficacy and safety of the subcutaneous implantable cardioverter defibrillator (S-ICD) compared with a transvenous ICD (TV-ICD) and showed noninferiority of the S-ICD with regard to the composite end point of device-related complications and inappropriate shocks after 49.1 months. Complications associated with transvenous leads are expected to occur after longer follow-up. The PRAETORIAN-XL trial aims to investigate whether the S-ICD is superior to the TV-ICD with respect to device-related complications at 8-year follow-up.
104. Impact of Acute Antioxidant and Tetrahydrobiopterin (BH4) Administration on Locomotor Muscle Microvascular Function in Patients With Heart Failure.
作者: Stephen M Ratchford.;Heather L Clifton.;Jayson R Gifford.;D Taylor LaSalle.;Taylor S Thurston.;Kanokwan Bunsawat.;Jeremy K Alpenglow.;Josephine B Wright.;Markus Amann.;John J Ryan.;D Walter Wray.
来源: Circ Heart Fail. 2025年18卷6期e012446页
Peripheral microvascular dysfunction is a hallmark feature of both heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) pathophysiology, due partly to impairments in nitric oxide signaling secondary to tetrahydrobiopterin (BH4) deficiency and oxidative stress.
105. Efficacy of the Glucagon-Like Peptide-1 Agonist Exenatide in Patients Undergoing CABG or Aortic Valve Replacement: A Randomized Double-Blind Clinical Trial.
作者: Jesper Kjaergaard.;Christian Holdflod Møller.;Sebastian Wiberg.;Astrid Duus Mikkelsen.;Hasse Møller-Sørensen.;Hanne Berg Ravn.;Jesper Ravn.;Peter Skov Olsen.;Dan E Høfsten.;Søren Boesgaard.;Lars Køber.;Jens Christian Nilsson.;Christian Hassager.
来源: Circ Cardiovasc Interv. 2025年18卷5期e014961页
GLP-1 (glucagon-like peptide-1) agonists have been proven beneficial in reducing the risk of and injury associated with several cardiovascular diseases. The efficacy in cardiopulmonary bypass-assisted cardiac surgery is unknown. This trial aimed to investigate the efficacy of an infusion of the GLP-1 agonist exenatide during and after open-heart surgery in reducing the risk of death and major organ failure.
106. Intensive Lowering of LDL Cholesterol Levels With Evolocumab in Autoimmune or Inflammatory Diseases: An Analysis of the FOURIER Trial.
作者: Andre Zimerman.;Ana Laura F Kunzler.;Brittany N Weber.;Xinhui Ran.;Sabina A Murphy.;Huei Wang.;Narimon Honarpour.;Anthony C Keech.;Peter S Sever.;Marc S Sabatine.;Robert P Giugliano.
来源: Circulation. 2025年151卷20期1467-1476页
Patients with an autoimmune or inflammatory disease (AIID) are at increased cardiovascular risk and may benefit more from statin therapy. In the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), the PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor evolocumab lowered low-density lipoprotein cholesterol levels, but not hsCRP (high-sensitivity C-reactive protein) levels, and reduced the risk of cardiovascular events.
107. Relationship Between Remote, Ambulatory Pulmonary Artery Pressures, and All-Cause Mortality in Patients With Chronic Heart Failure.
作者: Michael R Zile.;William T Abraham.;Lynne W Stevenson.;Maria Rosa Costanzo.;Christiane E Angermann.;Mandeep R Mehra.;Akshay S Desai.;Anique Ducharme.;Nessa Johnson.;John Henderson.;JoAnn Lindenfeld.
来源: Circ Heart Fail. 2025年18卷6期e012754页
Hemodynamically guided management of patients with chronic heart failure (HF), using a remote, ambulatory pulmonary artery (PA) pressure monitor, has been shown to reduce mortality and morbidity. These improved outcomes were associated with a reduction in PA pressure. However, several pivotal questions remain unanswered: do systolic, diastolic, or mean PA pressures each predict all-cause mortality? Do PA pressures predict mortality across the ejection fraction (EF) spectrum? Do increases or decreases in PA pressure over time predict increases or decreases in mortality?
108. Impact of In-Hospital Quality of Care Improvement Initiative on Secondary Prevention of Acute Coronary Syndrome in Six Months After Patient Discharge: A Large Stepped Wedge- and Cluster-Randomized Controlled Trial.
作者: Gaoqiang Xie.;Anushka Patel.;Xin Du.;Yihong Sun.;Xian Li.;Tao Wu.;Zhixin Hao.;Runlin Gao.;Yangfeng Wu.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷5期e011441页
Patients discharged after acute coronary syndrome experience a high risk of major adverse cardiovascular events (MACE) within the first 6 months. We examined whether a quality of care improvement initiative implemented in hospitals affects clinical preventive management and outcomes after discharge.
109. Comparing the Efficacy of Sirolimus and Paclitaxel-Eluting Balloon Catheters in the Treatment of Coronary In-Stent Restenosis: A Prospective Randomized Study (TIS 2 Study).
作者: Leos Pleva.;Pavel Kukla.;Tomas Kovarnik.;Jana Zapletalova.
来源: Circ Cardiovasc Interv. 2025年18卷5期e014677页
Current therapy for in-stent restenosis (ISR) is based on drug-eluting stents (DES) or drug-eluting balloon catheters. This prospective randomized study compared the efficacy of a novel sirolimus-eluting balloon (SEB) catheter to that of a paclitaxel-eluting balloon (PEB) catheter for the treatment of bare-metal stent (BMS-ISR) or DES-ISR.
110. A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure.
作者: Signe Glargaard.;Jakob Hartvig Thomsen.;Christian Tuxen.;Matias Greve Lindholm.;Christian Axel Bang.;Morten Schou.;Kasper Iversen.;Rasmus Vedby Rasmussen.;Brian Bridal Løgstrup.;Søren Vraa.;Nis Stride.;Ekim Seven.;Anders Barasa.;Marlene Tofterup.;Dan Eik Høfsten.;Kasper Rossing.;Lars Køber.;Finn Gustafsson.;Jens Jakob Thune.
来源: Circulation. 2025年151卷16期1150-1161页
TAP-IT (Thoracentesis to Alleviate Cardiac Pleural Effusion-Interventional Trial) investigated the effect of therapeutic thoracentesis in addition to standard medical therapy in patients with acute heart failure and sizeable pleural effusion.
111. Cardiac Biomarkers in Patients With Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial.
作者: Brian R Lindman.;Philippe Pibarot.;Allan Schwartz.;J Bradley Oldemeyer.;Yan Ru Su.;Kashish Goel.;David J Cohen.;William F Fearon.;Vasilis Babaliaros.;David Daniels.;Adnan Chhatriwalla.;Hussam S Suradi.;Pinak Shah.;Molly Szerlip.;Michael J Mack.;Thom Dahle.;William W O'Neill.;Charles J Davidson.;Raj Makkar.;Tej Sheth.;Jeremiah Depta.;James T DeVries.;Jeffrey Southard.;Andrei Pop.;Paul Sorajja.;Rebecca T Hahn.;Yanglu Zhao.;Martin B Leon.;Philippe Généreux.; .
来源: Circulation. 2025年151卷22期1550-1564页
The EARLY TAVR trial (Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis) demonstrated that early transcatheter aortic valve replacement (TAVR) intervention was superior to clinical surveillance with delayed TAVR in patients with asymptomatic severe aortic stenosis. Cardiac biomarkers are associated with maladaptive remodeling, symptom onset, and worse outcomes after TAVR. Whether elevated biomarkers identify asymptomatic patients more likely to benefit from early intervention is unknown.
112. Short-Term DAPT After Complex PCI With Third-Generation DES: A Post Hoc Analysis of the HOST-IDEA Trial.
作者: Jung-Kyu Han.;Keehwan Lee.;Sang-Hyeon Park.;Seokhun Yang.;Doyeon Hwang.;Jeehoon Kang.;Han-Mo Yang.;Kyung Woo Park.;Hyun-Jae Kang.;Bon-Kwon Koo.;Seung-Ho Hur.;Weon Kim.;Sang-Hyun Park.;Seung Hwan Han.;Sang-Hyun Kim.;Yong Hoon Kim.;Namho Lee.;Seung Jin Lee.;Sanghoon Shin.;Hyo-Soo Kim.
来源: Circ Cardiovasc Interv. 2025年18卷5期e014623页
The optimal duration of dual antiplatelet therapy (DAPT) after complex percutaneous coronary intervention (PCI) remains unclear. We aim to investigate the efficacy and safety of 3 to 6 months of DAPT over 12 months after complex PCI.
113. Electronic Provider Notification to Facilitate the Recognition and Management of Severe Aortic Stenosis: A Randomized Clinical Trial.
作者: Varsha Keelara Tanguturi.;Roukoz Abou-Karam.;Fangzhou Cheng.;Rong Duan.;Ignacio Inglessis-Azuaje.;Nathaniel B Langer.;Evin N Yucel.;Jonathan J Passeri.;Judy W Hung.;Sammy Elmariah.
来源: Circulation. 2025年151卷21期1498-1507页
Symptomatic severe aortic stenosis (AS) remains undertreated with high resultant mortality despite increased growth and availability of aortic valve replacement (AVR) since the advent of transcatheter therapies. We evaluate the impact of electronic provider notifications (EPNs) on rates of AVR at 1 year.
114. Effect of Red Blood Cell Transfusion Strategy on Clinical Outcomes Among Patients With Acute Myocardial Infarction Undergoing Revascularization: A Prespecified Analysis of the MINT Trial.
作者: Sunil V Rao.;Maria Mori Brooks.;Helen E A D'Agostino.;P Gabriel Steg.;Tabassome Simon.;Herbert D Aronow.;Andrew M Goldsweig.;Shahbaz Malik.;Caroline Alsweiler.;Kalon K L Ho.;Payam Dehghani.;Adriano Caixeta.;Ata R Quraishi.;Simon Robinson.;Jay H Traverse.;Omar Siddiqi.;Dean A Fergusson.;Brian J Potter.;Joshua Schulman-Marcus.;Friederike K Keating.;Jeffrey L Carson.; .
来源: Circ Cardiovasc Interv. 2025年18卷5期e015249页
The MINT trial (Myocardial Ischemia and Transfusion; N=3504) randomized patients with acute myocardial infarction (MI) and hemoglobin ≤10 g/dL to liberal (maintain hemoglobin ≥10 g/dL) or restrictive (maintain hemoglobin ≥8 g/dL) red blood cell transfusion. The results suggested a benefit on 30-day death or MI with a liberal transfusion strategy. The effect of transfusion in patients with acute MI undergoing revascularization is unclear.
115. Two-Year Outcomes of Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: The TRILUMINATE Pivotal Randomized Controlled Trial.
作者: Saibal Kar.;Raj R Makkar.;Brian K Whisenant.;Nadira Hamid.;Hursh Naik.;Peter Tadros.;Matthew J Price.;Gagan Singh.;Jonathan G Schwartz.;Samir Kapadia.;Oluseun Alli.;Samuel Horr.;Puvi Seshiah.;Wayne Batchelor.;Brandon M Jones.;Mustafa I Ahmed.;Raymond Benza.;Ulrich Jorde.;Vinod H Thourani.;Andrew A Ghobrial.;Gilbert H L Tang.;Phillip M Trusty.;Dina Huang.;Rebecca T Hahn.;David H Adams.;Paul Sorajja.; .
来源: Circulation. 2025年151卷23期1630-1638页
One-year outcomes of TRILUMINATE Pivotal (Trial to Evaluate Cardiovascular Outcomes in Patients Treated With the Tricuspid Valve Repair System Pivotal) found that transcatheter edge-to-edge repair (TEER) for the treatment of severe, symptomatic tricuspid regurgitation improved quality of life compared with medical therapy alone with similar rates of mortality and heart failure hospitalization. However, additional follow-up is necessary to determine the prolonged benefits of tricuspid TEER.
116. Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.
作者: Nikolaus Marx.;John E Deanfield.;Johannes F E Mann.;Rosario Arechavaleta.;Stephen C Bain.;Harpreet S Bajaj.;Katrine Bayer Tanggaard.;Andreas L Birkenfeld.;John B Buse.;Zaklina Davicevic-Elez.;Cyrus Desouza.;Scott S Emerson.;Mads D M Engelmann.;G Kees Hovingh.;Silvio E Inzucchi.;Pardeep S Jhund.;Sharon L Mulvagh.;Rodica Pop-Busui.;Neil R Poulter.;Søren Rasmussen.;Shih-Te Tu.;Darren K McGuire.; .
来源: Circulation. 2025年151卷23期1639-1650页
Both GLP-1 (glucagon-like peptide-1) receptor agonists and SGLT2 (sodium-glucose cotransporter-2) inhibitors (SGLT2i) improve cardiovascular outcomes in people with type 2 diabetes and cardiovascular or chronic kidney disease. However, there are limited data about the effect of combining these agents on cardiovascular and safety outcomes.
117. Effect of Disclosing a Polygenic Risk Score for Coronary Heart Disease on Adverse Cardiovascular Events.
作者: Mohammadreza Naderian.;Marwan E Hamed.;Ali A Vaseem.;Kristjan Norland.;Ozan Dikilitas.;Azin Teymourzadeh.;Kent R Bailey.;Iftikhar J Kullo.
来源: Circ Genom Precis Med. 2025年18卷2期e004968页
In the Myocardial Infarction Genes clinical trial (URL: https://www.clinicaltrials.gov; Unique identifier: NCT01936675), participants at intermediate risk of coronary heart disease (CHD) were randomized to receive a Framingham risk score (Framingham risk score group, n=103) or an integrated risk score (integrated risk score group [IRSg], n=104) that additionally included a polygenic risk score. After 6 months, IRSg participants had higher statin initiation and lower low-density lipoprotein cholesterol. We conducted a post hoc 10-year follow-up analysis to investigate whether disclosure of a polygenic risk score for CHD was associated with a reduction in major adverse cardiovascular events (MACE).
118. Alcohol Exposure Among Patients With Dilated Cardiomyopathy and Their First-Degree Relatives: The DCM Precision Medicine Study.
作者: Javier Jimenez.;Hanyu Ni.;Stuart D Katz.;Garrie J Haas.;Jinwen Cao.;Muni Rubens.;Sandra Chaparro.;Anshul Saxena.;Mark Hofmeyer.;Evan Kransdorf.;Gregory A Ewald.;Alanna A Morris.;Anjali Owens.;Brian Lowes.;Douglas Stoller.;W H Wilson Tang.;Palak Shah.;Jane E Wilcox.;Frank Smart.;Jessica Wang.;Stephen S Gottlieb.;Daniel P Judge.;Jonathan O Mead.;Natalie Hurst.;Patricia K Parker.;Gordon S Huggins.;Elizabeth Jordan.;Daniel D Kinnamon.;Ray E Hershberger.; .
来源: Circ Genom Precis Med. 2025年18卷2期e004946页
Whether prolonged and excessive alcohol consumption contributes to dilated cardiomyopathy (DCM) remains uncertain. This study aimed to describe the prevalence of alcohol use in patients with DCM and their first-degree relatives (FDRs) and determine if cumulative alcohol exposure associates with DCM/partial DCM or modifies the association of DCM with DCM-relevant rare variants.
119. Blood Transfusion in Patients With Acute Myocardial Infarction, Anemia, and Heart Failure: Lessons From MINT.
作者: Andrew M Goldsweig.;William J Kostis.;Brandon M Herbert.;Claire Bouleti.;Brian J Potter.;Jordan B Strom.;Jocelyne Benatar.;Thao Huynh.;Srikanth Vallurupalli.;Estêvão Lanna Figueiredo.;J Dawn Abbott.;Howard A Cooper.;Andrew P DeFilippis.;Dean A Fergusson.;Shaun G Goodman.;Paul C Hébert.;Renato D Lopes.;Sunil V Rao.;Tabassome Simon.;Jeffrey L Carson.;Maria Mori Brooks.;John H Alexander.; .
来源: Circ Heart Fail. 2025年18卷4期e012495页
Blood transfusion may precipitate adverse outcomes, including heart failure (HF), among patients with acute myocardial infarction (MI). This study characterizes the effects of a restrictive or liberal transfusion strategy on outcomes in patients with MI and anemia with and without baseline HF.
120. Effects of Nicorandil, Isosorbide Mononitrate, or Diltiazem on Radial Artery Grafts After CABG: The Randomized ASRAB-Pilot Trial.
作者: Yunpeng Zhu.;Wei Zhang.;Kaijie Qin.;Yun Liu.;Haoyi Yao.;Zhe Wang.;Xiaofeng Ye.;Mi Zhou.;Haiqing Li.;Jiapei Qiu.;Hong Xu.;Yanjun Sun.;Mario Gaudino.;Qiang Zhao.
来源: Circ Cardiovasc Interv. 2025年18卷4期e014542页
The optimal antispastic treatment after coronary artery bypass grafting using radial artery (RA) grafts is controversial. This clinical trial aimed to generate pilot comparative data on the effects of nicorandil, isosorbide mononitrate, or diltiazem on RA grafts.
|